ARTICLES BY YULIA PRIVOLNEV
What’s A Cure Worth? ICER Publishes Value Assessment Framework For Curative Therapies8/27/2019
The Institute for Clinical and Economic Review (ICER) recently conducted a study of value assessment methods considered for “cures” or “potential cures” and solicited input from international HTA bodies. The research will form the basis of a value framework that will be applied in the assessment of potential cures and other treatments that qualify as what ICER refers to as “single or short-term transformative therapies.”
CAR T-Cell Therapies In The EU5: What Can We Expect From Payers?1/24/2019
The difficulty of balancing paying for innovation with budgets has plagued Europe for years, and the emergence of cell and gene therapies has only exacerbated that conundrum.